Recce Pharmaceuticals Secures FDA QIDP Status and Expands Phase 3 Trial for RECCE® 327 Gel, Advancing Commercial Launch Plans

RECCE® 327 Gains U.S. FDA QIDP Designation and WHO Clinical Development Recognition

Recce Pharmaceuticals announced that RECCE® 327, its lead anti-infective gel candidate, has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration. This status provides 10 years of market exclusivity post-approval and enables fast-track approval pathways, significantly enhancing Recce’s competitive position in the global anti-infective market. The QIDP designation also helps expedite regulatory review in the U.S., potentially accelerating product availability.

Simultaneously, RECCE® 327 was added to the World Health Organization’s List of Antibacterial Products in Clinical Development, underscoring its global importance in combating antimicrobial resistance. This recognition elevates Recce’s standing in the international healthcare community and reinforces confidence in RECCE® 327’s potential to address critical unmet medical needs related to multidrug-resistant bacterial infections.

Expanded Phase 3 Trial in Indonesia and Protocol Enhancements Support Accelerated Global Registration

Recce’s Phase 3 clinical trial in Indonesia for RECCE® 327 Gel has broadened patient eligibility to include those with moderate diabetic foot infections, expanding beyond the initial focus on severe cases. This strategic expansion increases the recruitment pool and may accelerate enrolment. Patient dosing under the revised criteria is underway, with an interim data readout targeted for Q3 2026.

Supporting this progression, the Australian human research ethics committee approved protocol amendments that incorporate ulcer-level endpoint analyses, enhancing the trial’s statistical power and clinical relevance. These changes facilitate an accelerated global registration strategy, enabling Recce to conduct two concurrent Phase 3 registrational trials. This approach aims to generate pivotal data for regulatory submissions across multiple markets simultaneously, with commercialisation projected for 2027.

Indonesia’s Regulatory Authority Completes Inspection with No Findings

Indonesia’s regulatory body, BPOM (Badan Pengawas Obat dan Makanan), conducted a comprehensive inspection of Recce’s Phase 3 trial operations and reported no findings or required changes. This clean inspection confirms compliance with Indonesia’s clinical trial standards and regulatory requirements, mitigating risks associated with trial conduct and data integrity.

Given Indonesia’s significance—home to over 20 million adults with diabetes—this regulatory clearance is crucial. It removes potential obstacles to trial advancement and strengthens the credibility of clinical data for submission to global regulators, including the FDA and European Medicines Agency.

Non-Binding Licensing Term Sheet with Middle Eastern Pharma Marks Key Commercialisation Milestone

Recce signed a non-binding term sheet with a leading Middle Eastern pharmaceutical company proposing a 10-year exclusive multi-country licensing agreement. This deal validates RECCE® 327’s commercial potential and reflects strong regional industry interest. The agreement structure includes upfront payments, milestone payments tied to clinical and regulatory milestones, revenue sharing, and royalties.

The Middle East and North Africa (MENA) region, with over 84 million adults living with diabetes, represents a significant market opportunity. Partnering with a regional pharmaceutical leader provides Recce with established distribution networks and market access, reducing direct market entry costs and risks. The upfront and milestone payments are expected to provide Recce with near-term capital to support ongoing clinical development while retaining long-term financial upside through royalties and revenue sharing.

Global Diabetic Foot Infection Market Highlights Unmet Medical Need and Commercial Potential

The global diabetic foot infection treatment market is estimated at US$5.8 billion, within a broader anti-infectives market valued at US$135.4 billion. Approximately 589 million adults worldwide live with diabetes, with about one-third developing diabetic foot ulcers during their lifetime, highlighting a substantial patient population in need of improved therapies.

In Indonesia, diabetic foot infections are severe in 67.1% of hospitalised cases and lead to amputation in 46.9% of patients, emphasizing the urgent need for effective treatments. These statistics underscore the potential clinical and economic impact of a fast-acting therapy like RECCE® 327.

Diverse Clinical Indications and Formulations Position Recce for Sustainable Growth

While RECCE® 327 Gel’s near-term focus is diabetic foot infections, Recce is developing multiple indications and formulations to address other unmet needs. The company has agreements with the U.S. Defense Burn Research Program and the U.S. Army Medical Research Institute of Infectious Diseases, exploring applications in burn wound treatment and military medicine.

This diversification strategy aims to maximize the commercial potential of Recce’s anti-infective platform, with prospects for expansion into burn wound infections, chronic wounds, and other antimicrobial-resistant infections. Collaborations with U.S. defense institutions also position Recce as a supplier for military medical applications, creating additional revenue streams beyond civilian healthcare.

RECCE® 327’s Mechanism of Action Tackles the Global Antibiotic Resistance Crisis

Recce Pharmaceuticals is dedicated to combating the global antibiotic resistance crisis. RECCE® 327 acts faster than traditional antibiotics and is effective against multidrug-resistant bacteria, addressing critical limitations of current therapies. This rapid mechanism offers a clinical advantage in severe infections requiring swift control, such as diabetic foot infections and burn wounds.

The World Health Organization recognizes antibiotic resistance as a major public health threat. RECCE® 327’s inclusion on the WHO’s List of Antibacterial Products in Clinical Development highlights its potential as an important tool in fighting antimicrobial resistance worldwide.

Financial Terms of Middle Eastern Licensing Deal and Capital Impact

The proposed licensing agreement with the Middle Eastern partner features a multi-tiered financial structure including upfront payments, milestone payments, revenue sharing, and royalties. While exact financial terms remain undisclosed, the structure suggests immediate capital inflows to support Recce’s clinical and commercial activities, alongside long-term revenue participation contingent on product success.

This risk-sharing model allows Recce to retain intellectual property and regulatory responsibilities while leveraging the partner’s regional commercial expertise and infrastructure. The arrangement de-risks Recce’s commercialisation efforts and provides validation from an established pharmaceutical entity.

Commercialisation Timeline and Interim Phase 3 Data Expected in Q3 2026

Recce anticipates an interim data readout from its Indonesian Phase 3 trial in Q3 2026, offering early insights into efficacy, safety, and tolerability. This milestone will inform potential trial adjustments and regulatory strategies. The company targets commercial launch of RECCE® 327 in 2027, contingent on positive trial outcomes and regulatory approvals.

Conducting two concurrent Phase 3 registrational trials in Indonesia and Australia enables simultaneous data generation for multiple regulatory submissions. The interval between the interim data release and commercialisation allows time for final data analysis, submission preparation, and regulatory review across jurisdictions. Investors should closely monitor the Q3 2026 interim data as a key validation point for RECCE® 327’s clinical profile.